Literature DB >> 35142156

The impact of aberrant von Willebrand factor-GPIbα interaction on megakaryopoiesis and platelets in humanized type 2B von Willebrand disease model mouse.

Sachiko Kanaji1, Yosuke Morodomi2, Hartmut Weiler3, Alessandro Zarpellon4, Robert R Montgomery5, Zaverio M Ruggeri4, Taisuke Kanaji6.   

Abstract

Type 2B von Willebrand disease (VWD) is caused by gain-of-function mutations in von Willebrand factor (VWF). Increased VWF affinity for GPIba results in loss of high molecular weight multimers and enhanced platelet clearance, both contributing to the bleeding phenotype. Severity of the symptoms vary among type 2B VWD patients, with some developing thrombocytopenia only under stress conditions. Efforts have been made to study underlying pathophysiology for platelet abnormalities, but animal studies have been limited because of species specificity in the VWF-GPIba interaction. Here, we generated a severe form of type 2B VWD (p.V1316M) knockin mice in the context of human VWF exon 28 (encoding A1 and A2 domains) and crossed them with human GPIba transgenic strain. Heterozygous mutant mice recapitulated the phenotype of type 2B VWD in autosomal dominant manner and presented severe macrothrombocytopenia. Of note, platelets remaining in the circulation had extracytoplasmic GPIba shed-off from the cell surface. Reciprocal bone marrow transplantation determined mutant VWF produced from endothelial cells as the major cause of the platelet phenotype in type 2B VWD mice. Moreover, altered megakaryocyte maturation in the bone marrow and enhanced extramedullary megakaryopoiesis in the spleen were observed. Interestingly, injection of anti-VWF A1 blocking antibody (NMC-4) not only ameliorated platelet count and GPIba expression, but also reversed MK ploidy shift. In conclusion, we present a type 2B VWD mouse model with humanized VWF-GPIba interaction which demonstrated direct influence of aberrant VWF-GPIba binding on megakaryocytes.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35142156      PMCID: PMC9425322          DOI: 10.3324/haematol.2021.280561

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   11.047


  42 in total

1.  GPIbα regulates platelet size by controlling the subcellular localization of filamin.

Authors:  Taisuke Kanaji; Jerry Ware; Takashi Okamura; Peter J Newman
Journal:  Blood       Date:  2011-12-15       Impact factor: 22.113

2.  Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis.

Authors:  S Kanaji; S A Fahs; Q Shi; S L Haberichter; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

3.  LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B.

Authors:  Alexandre Kauskot; Sonia Poirault-Chassac; Frédéric Adam; Vincent Muczynski; Gabriel Aymé; Caterina Casari; Jean-Claude Bordet; Christelle Soukaseum; Chantal Rothschild; Valérie Proulle; Audrey Pietrzyk-Nivau; Eliane Berrou; Olivier D Christophe; Jean-Philippe Rosa; Peter J Lenting; Marijke Bryckaert; Cécile V Denis; Dominique Baruch
Journal:  JCI Insight       Date:  2016-10-06

4.  Crystal structure of NMC-4 fab anti-von Willebrand factor A1 domain.

Authors:  R Celikel; K I Varughese; M Shima; A Yoshioka; J Ware; Z M Ruggeri
Journal:  Blood Cells Mol Dis       Date:  1997       Impact factor: 3.039

5.  Roles of spleen and liver in development of the murine hematopoietic system.

Authors:  Frances M Wolber; Ellen Leonard; Sara Michael; Christie M Orschell-Traycoff; Mervin C Yoder; Edward F Srour
Journal:  Exp Hematol       Date:  2002-09       Impact factor: 3.084

6.  A novel interaction between FlnA and Syk regulates platelet ITAM-mediated receptor signaling and function.

Authors:  Hervé Falet; Alice Y Pollitt; Antonija Jurak Begonja; Sarah E Weber; Daniel Duerschmied; Denisa D Wagner; Steve P Watson; John H Hartwig
Journal:  J Exp Med       Date:  2010-08-16       Impact factor: 14.307

7.  Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases.

Authors:  E E Gardiner; D Karunakaran; Y Shen; J F Arthur; R K Andrews; M C Berndt
Journal:  J Thromb Haemost       Date:  2007-04-18       Impact factor: 5.824

8.  Visualizing the von Willebrand factor/glycoprotein Ib-IX axis with a platelet-type von Willebrand disease mutation.

Authors:  Jose A Guerrero; Mark Kyei; Susan Russell; Junling Liu; T Kent Gartner; Brian Storrie; Jerry Ware
Journal:  Blood       Date:  2009-10-06       Impact factor: 22.113

9.  Platelet dysfunction and a high bone mass phenotype in a murine model of platelet-type von Willebrand disease.

Authors:  Larry J Suva; Eric Hartman; Joshua D Dilley; Susan Russell; Nisreen S Akel; Robert A Skinner; William R Hogue; Ulrich Budde; Kottayil I Varughese; Taisuke Kanaji; Jerry Ware
Journal:  Am J Pathol       Date:  2008-01-10       Impact factor: 4.307

10.  The rapid differentiation of type IIb von Willebrand's disease from platelet-type (pseudo-) von Willebrand's disease by the "neutral" monoclonal antibody binding assay.

Authors:  J P Scott; R R Montgomery
Journal:  Am J Clin Pathol       Date:  1991-12       Impact factor: 2.493

View more
  1 in total

Review 1.  Neuroprotective Effects of Quercetin on Ischemic Stroke: A Literature Review.

Authors:  Leilei Zhang; Jingying Ma; Fan Yang; Sishi Li; Wangran Ma; Xiang Chang; Lin Yang
Journal:  Front Pharmacol       Date:  2022-05-18       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.